221 related articles for article (PubMed ID: 18210157)
1. Exploring gene-environment interactions in Parkinson's disease.
McCulloch CC; Kay DM; Factor SA; Samii A; Nutt JG; Higgins DS; Griffith A; Roberts JW; Leis BC; Montimurro JS; Zabetian CP; Payami H
Hum Genet; 2008 Apr; 123(3):257-65. PubMed ID: 18210157
[TBL] [Abstract][Full Text] [Related]
2. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.
Mata IF; Leverenz JB; Weintraub D; Trojanowski JQ; Hurtig HI; Van Deerlin VM; Ritz B; Rausch R; Rhodes SL; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Peterson AL; Espay AJ; Revilla FJ; Devoto J; Hu SC; Cholerton BA; Wan JY; Montine TJ; Edwards KL; Zabetian CP
JAMA Neurol; 2014 Nov; 71(11):1405-12. PubMed ID: 25178429
[TBL] [Abstract][Full Text] [Related]
3. SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians.
Huang Y; Wang G; Rowe D; Wang Y; Kwok JB; Xiao Q; Mastaglia F; Liu J; Chen SD; Halliday G
Biomed Res Int; 2015; 2015():135674. PubMed ID: 25960998
[TBL] [Abstract][Full Text] [Related]
4. Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions.
Chung SJ; Armasu SM; Anderson KJ; Biernacka JM; Lesnick TG; Rider DN; Cunningham JM; Ahlskog JE; Frigerio R; Maraganore DM
Parkinsonism Relat Disord; 2013 Jun; 19(6):595-9. PubMed ID: 23507417
[TBL] [Abstract][Full Text] [Related]
5. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.
Maraganore DM; de Andrade M; Elbaz A; Farrer MJ; Ioannidis JP; Krüger R; Rocca WA; Schneider NK; Lesnick TG; Lincoln SJ; Hulihan MM; Aasly JO; Ashizawa T; Chartier-Harlin MC; Checkoway H; Ferrarese C; Hadjigeorgiou G; Hattori N; Kawakami H; Lambert JC; Lynch T; Mellick GD; Papapetropoulos S; Parsian A; Quattrone A; Riess O; Tan EK; Van Broeckhoven C;
JAMA; 2006 Aug; 296(6):661-70. PubMed ID: 16896109
[TBL] [Abstract][Full Text] [Related]
6. Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?
Biernacka JM; Armasu SM; Cunningham JM; Ahlskog JE; Chung SJ; Maraganore DM
Parkinsonism Relat Disord; 2011 Dec; 17(10):730-6. PubMed ID: 21816655
[TBL] [Abstract][Full Text] [Related]
7. SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population.
Trotta L; Guella I; Soldà G; Sironi F; Tesei S; Canesi M; Pezzoli G; Goldwurm S; Duga S; Asselta R
Parkinsonism Relat Disord; 2012 Mar; 18(3):257-62. PubMed ID: 22104010
[TBL] [Abstract][Full Text] [Related]
8. UCHL1 S18Y variant is a risk factor for Parkinson's disease in Japan.
Miyake Y; Tanaka K; Fukushima W; Kiyohara C; Sasaki S; Tsuboi Y; Yamada T; Oeda T; Shimada H; Kawamura N; Sakae N; Fukuyama H; Hirota Y; Nagai M;
BMC Neurol; 2012 Jul; 12():62. PubMed ID: 22839974
[TBL] [Abstract][Full Text] [Related]
9. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.
Elbaz A; Ross OA; Ioannidis JP; Soto-Ortolaza AI; Moisan F; Aasly J; Annesi G; Bozi M; Brighina L; Chartier-Harlin MC; Destée A; Ferrarese C; Ferraris A; Gibson JM; Gispert S; Hadjigeorgiou GM; Jasinska-Myga B; Klein C; Krüger R; Lambert JC; Lohmann K; van de Loo S; Loriot MA; Lynch T; Mellick GD; Mutez E; Nilsson C; Opala G; Puschmann A; Quattrone A; Sharma M; Silburn PA; Stefanis L; Uitti RJ; Valente EM; Vilariño-Güell C; Wirdefeldt K; Wszolek ZK; Xiromerisiou G; Maraganore DM; Farrer MJ;
Ann Neurol; 2011 May; 69(5):778-92. PubMed ID: 21391235
[TBL] [Abstract][Full Text] [Related]
10. Common variants in PARK loci and related genes and Parkinson's disease.
Chung SJ; Armasu SM; Biernacka JM; Lesnick TG; Rider DN; Lincoln SJ; Ortolaza AI; Farrer MJ; Cunningham JM; Rocca WA; Maraganore DM
Mov Disord; 2011 Feb; 26(2):280-8. PubMed ID: 21412835
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.
Heckman MG; Elbaz A; Soto-Ortolaza AI; Serie DJ; Aasly JO; Annesi G; Auburger G; Bacon JA; Boczarska-Jedynak M; Bozi M; Brighina L; Chartier-Harlin MC; Dardiotis E; Destée A; Ferrarese C; Ferraris A; Fiske B; Gispert S; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lin CH; Lohmann K; Loriot MA; Lynch T; Mellick GD; Mutez E; Opala G; Park SS; Petrucci S; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Tomiyama H; Uitti RJ; Valente EM; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Xiromerisiou G; Maraganore DM; Farrer MJ; Ross OA;
Neurobiol Aging; 2014 Jan; 35(1):266.e5-14. PubMed ID: 23962496
[TBL] [Abstract][Full Text] [Related]
12. Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.
Huang Y; Rowe DB; Halliday GM
J Parkinsons Dis; 2011; 1(3):271-6. PubMed ID: 23939307
[TBL] [Abstract][Full Text] [Related]
13. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.
Mata IF; Shi M; Agarwal P; Chung KA; Edwards KL; Factor SA; Galasko DR; Ginghina C; Griffith A; Higgins DS; Kay DM; Kim H; Leverenz JB; Quinn JF; Roberts JW; Samii A; Snapinn KW; Tsuang DW; Yearout D; Zhang J; Payami H; Zabetian CP
Arch Neurol; 2010 Nov; 67(11):1350-6. PubMed ID: 21060011
[TBL] [Abstract][Full Text] [Related]
14. Head injury, α-synuclein Rep1, and Parkinson's disease.
Goldman SM; Kamel F; Ross GW; Jewell SA; Bhudhikanok GS; Umbach D; Marras C; Hauser RA; Jankovic J; Factor SA; Bressman S; Lyons KE; Meng C; Korell M; Roucoux DF; Hoppin JA; Sandler DP; Langston JW; Tanner CM
Ann Neurol; 2012 Jan; 71(1):40-8. PubMed ID: 22275250
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study.
Brighina L; Schneider NK; Lesnick TG; de Andrade M; Cunningham JM; Mrazek D; Rocca WA; Maraganore DM
Parkinsonism Relat Disord; 2009 Jul; 15(6):430-4. PubMed ID: 19196539
[TBL] [Abstract][Full Text] [Related]
16. Genetic association between alpha-synuclein and idiopathic Parkinson's disease.
Kay DM; Factor SA; Samii A; Higgins DS; Griffith A; Roberts JW; Leis BC; Nutt JG; Montimurro JS; Keefe RG; Atkins AJ; Yearout D; Zabetian CP; Payami H
Am J Med Genet B Neuropsychiatr Genet; 2008 Oct; 147B(7):1222-30. PubMed ID: 18404644
[TBL] [Abstract][Full Text] [Related]
17. SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study.
Wider C; Vilariño-Güell C; Heckman MG; Jasinska-Myga B; Ortolaza-Soto AI; Diehl NN; Crook JE; Cobb SA; Bacon JA; Aasly JO; Gibson JM; Lynch T; Uitti RJ; Wszolek ZK; Farrer MJ; Ross OA
Eur J Neurol; 2011 Jun; 18(6):876-81. PubMed ID: 21159074
[TBL] [Abstract][Full Text] [Related]
18. Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age.
Liu Y; Chen YY; Liu H; Yao CJ; Zhu XX; Chen DJ; Yang J; Lu YJ; Cao JY
Neurol Sci; 2015 Feb; 36(2):179-88. PubMed ID: 25370916
[TBL] [Abstract][Full Text] [Related]
19. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
[TBL] [Abstract][Full Text] [Related]
20. Transcript Variants of Genes Involved in Neurodegeneration Are Differentially Regulated by the APOE and MAPT Haplotypes.
Koks S; Pfaff AL; Bubb VJ; Quinn JP
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
